It looked like an over reaction this morning for a company that increased earnings, again.
Resmed is in a hot sector and targets a unique health problem.
Sleep Apnea still remains under-diagnosed which will provide RMD growth for years to come. Imo it could also be a acquisition target by an American health giant given its growth potential and cash flow.
A nice top up opportunity.
Ann: ResMed Announces Results for the Second Quarter of FY 2019, page-51
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.28 |
Change
0.200(0.54%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.50 | $37.55 | $37.15 | $17.93M | 480.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3363 | $37.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.30 | 1001 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
